China Scandal One Early Challenge For New GSK Chairman
This article was originally published in PharmAsia News
Executive Summary
Philip Hampton likely will have to deal with the fallout from the Chinese bribery scandal, as well as a major restructuring of the previously announced asset swap with Novartis, and increasing generic competition to its leading products.